Company Coverage
Ping An Healthcare and Technology Company (1833 HK): 1H26: Bottom Line Beat On Margin Expansion; Non-core Business Run-off Weighs On 2026 Revenue
BUY (Maintained)
Current price:
Target price:
Upside:
Previous TP :
HK$7.13
HK$10.00
40.3%
HK$11.00
Analyst
Analyst
Highlights
- PAGD’s 1H26 revenue decreased 0.7% yoy amid run-off of non-core
business, while adjusted net profit rose 37.7% yoy on strong margin
expansion, beating our and consensus’ 2026 estimates.
- We lower 2026 revenue growth estimates to 0.2% yoy, but forecast revenue
and adjusted net profit CAGR of 14% and 35% for 2026-28, supported by
continued business mix optimisation towards corporate health management
and AI enablement.
- Maintain BUY with a lower target price of HK$10.00, with medium-term
earnings momentum still intact.
Analysis
- Bottom line beat in 1H26. Ping An Healthcare and Technology Company’s
(PAGD) 1H26 revenue declined by 0.7% yoy to Rmb2.48b, below our and
consensus’ 2026 estimates of 5.4% and 8.6% yoy. Adjusted net profit rose
37.7% yoy to Rmb227m in 1H26, beating our and consensus’ 2026 estimates
of 11.1% and 12.4% yoy. In 2Q26, revenue declined 8.0% yoy, while adjusted
net margin improved to 10.7% vs 7.6% in 2025 and 7.3% in 1Q26.
Highlights
- PAGD’s 1H26 revenue decreased 0.7% yoy amid run-off of non-core
business, while adjusted net profit rose 37.7% yoy on strong margin
expansion, beating our and consensus’ 2026 estimates.
- We lower 2026 revenue growth estimates to 0.2% yoy, but forecast revenue
and adjusted net profit CAGR of 14% and 35% for 2026-28, supported by
continued business mix optimisation towards corporate health management
and AI enablement.
- Maintain BUY with a lower target price of HK$10.00, with medium-term
earnings momentum still intact.
Analysis
- Bottom line beat in 1H26. Ping An Healthcare and Technology Company’s
(PAGD) 1H26 revenue declined by 0.7% yoy to Rmb2.48b, below our and
consensus’ 2026 estimates of 5.4% and 8.6% yoy. Adjusted net profit rose
37.7% yoy to Rmb227m in 1H26, beating our and consensus’ 2026 estimates
of 11.1% and 12.4% yoy. In 2Q26, revenue declined 8.0% yoy, while adjusted
net margin improved to 10.7% vs 7.6% in 2025 and 7.3% in 1Q26.
BUY (Maintained)
Current price:
Target price:
Upside:
Previous TP :
HK$7.13
HK$10.00
40.3%
HK$11.00
Analyst
Analyst
IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS
This report is provided subject to, and must be read together with, the full Disclosures / Disclaimers available at this link, which are incorporated by reference into this report. In particular, this report is intended for general circulation and informational purposes only and does not constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report. By accessing, receiving or using this report, you acknowledge that you have read, understood and agreed to be bound by the Disclosures / Disclaimers, as may be amended, supplemented or updated from time to time.
Related articles
20 Aug 2026
Hong Kong Exchanges and Clearing (388 HK): 2Q26: Strong Beat On Core Revenue Amid Turnover Surges
19 Aug 2026
Baidu Inc (9888 HK): 2Q26: Earnings Miss; AI Growth Accelerates, But Sustainability Remains To Be Proven
20 Aug 2026
Kuaishou Technology (1024 HK): 2Q26: Results Broadly In Line, But Outlook Weaker Than Expected
Our latest research
20 Aug 2026
TA: HKEX (0388 HK) / KE Holdings (2423 HK)
20 Aug 2026
Hong Kong Exchanges and Clearing (388 HK): 2Q26: Strong Beat On Core Revenue Amid Turnover Surges
20 Aug 2026